US-based cell and gene therapy company Cell BioEngines has announced its exclusive licencing agreement with Icahn School of Medicine at Mount Sinai in New York, US, for the development and worldwide commercialisation rights for differentiating most potent immune cells from stem cells and large-scale manufacturing.
Cell BioEngines announces exclusive licencing agreement for cancer cure
